Beam Therapeutics BEAM Non-Cash Lease Expense
Non-Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Beam Therapeutics’s 10-K, filed February 25, 2025, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's non-cash lease expense?
- Beam Therapeutics (BEAM) reported non-cash lease expense of $2.42M in Q4 2024.
- How has Beam Therapeutics's non-cash lease expense changed year-over-year?
- Beam Therapeutics's non-cash lease expense increased by 1.6% year-over-year, from $2.38M to $2.42M.
- What is the long-term trend for Beam Therapeutics's non-cash lease expense?
- Over 2 years (2022 to 2024), Beam Therapeutics's non-cash lease expense has grown at a 7.1% compound annual growth rate (CAGR), from $8.43M to $9.67M.
- What does non-cash lease expense mean?
- Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.